Discovery of liver-directed glucokinase activator having anti-hyperglycemic effect without hypoglycemia

Glucokinase activators (GKAs) are among the emerging drug candidates for the treatment of Type 2 Diabetes (T2D). Despite effective blood glucose lowering in clinical trials, many pan-GKAs "acting both in Pancreas and liver" have been discontinued from clinical development mainly because of their potential to cause Hypoglycemia. Pan-GKAs over sensitize pancreatic GK, resulting in Insulin secretion even at sub-normoglycemic level which might be a possible explanation for Hypoglycemia. An alternative approach to minimize the risk of Hypoglycemia is to use liver-directed GKAs, which are reported to be advancing well in clinical development. Here, we report the discovery and structure-activity relationship (SAR) studies on a novel 2-phenoxy-acetamide series with the aim of identifying a liver-directed GKA. Incorporation of a carboxylic acid moiety as an active hepatocyte uptake recognizing element at appropriate position of 2-phenoxy-acetamide core led to the identification of 26, a potent GKA with predominant liver-directed pharmacokinetics in mice. Compound 26 on oral administration significantly reduced blood glucose levels during an oral glucose tolerance test (oGTT) performed in diet-induced obese (DIO) mice, while showing no sign of Hypoglycemia in normal C57 mice over a 10-fold dose range, even when dosed at fasted condition. Together, these data demonstrate a liver-directed GKA has beneficial effect on glucose homeostasis with reduced risk of Hypoglycemia.